Table 2.

Proposed criteria rejected by the expert panel for inclusion in STOPP/START version 3 using Delphi consensus methodology

Rejected STOPP Criteria
Aspirin with a previous history of peptic ulcer disease without concomitant proton pump inhibitor (risk of recurrent peptic ulcer)
Mirabegron with known QTc interval prolongation (risk of exacerbation with associated ventricular arrhythmias)
Angiotensin converting enzyme inhibitors if eGFR < 30 ml/min/1.73m2 (risk of deterioration in renal function)
Angiotensin receptor blockers if eGFR < 30/min/1.73m2 (risk of deterioration in renal function)
Serotonin/noradrenaline reuptake inhibitors (SNRI’s e.g. venlafaxine, duloxetine) and chronic insomnia (likely to make insomnia worse)
Antiplatelet agents and Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors with a known history of cerebral amyloid angiopathy (increased risk of major intracerebral bleeding)
Thiazolidenediones (e.g. rosiglitazone, pioglitazone) with symptomatic hypotension (risk of exacerbation of hypotension)
Glucagon-like peptide-1 receptor (GLP-1) agonists (e.g. dulaglutide, exenatide, liraglutide, lixisenatide) with chronic constipation (risk of exacerbation of constipation)
Glucagon-like peptide-1 receptor (GLP-1) agonists (e.g. dulaglutide, exenatide, liraglutide, lixisenatide) with gastro-oesophageal reflux disease (risk of exacerbation of gastro-oesophageal reflux)
Mirabegron with current or previous tachyarrhythmia (risk of exacerbation or relapse of tachyarrhythmia)
Loop diuretics in patients with recurrent falls (may cause intravascular volume depletion and orthostatic hypotension)
Rejected START Criteria
Quinine sulphate in patients with recurrent painful lower limb muscle cramps
Memantine for moderate-severe Alzheimer’s disease